Your browser doesn't support javascript.
loading
Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay
James P Broughton; Xianding Deng; Guixia Yu; Clare L Fasching; Jasmeet Singh; Jessica Streithorst; Andrea Granados; Alicia Sotomayor-Gonzalez; Kelsey Zorn; Allan Gopez; Elaine Hsu; Wei Gu; Steven Miller; Chao-Yang Pan; Hugo Guevara; Debra Wadford; Janice Chen; Charles Y Chiu.
Affiliation
  • James P Broughton; Mammoth Biosciences, Inc.
  • Xianding Deng; University of California, San Francisco
  • Guixia Yu; University of California, San Francisco
  • Clare L Fasching; Mammoth Biosciences, Inc.
  • Jasmeet Singh; Mammoth Biosciences, Inc.
  • Jessica Streithorst; University of California, San Francisco
  • Andrea Granados; University of California, San Francisco
  • Alicia Sotomayor-Gonzalez; University of California, San Francisco
  • Kelsey Zorn; University of California, San Francisco
  • Allan Gopez; University of California, San Francisco
  • Elaine Hsu; University of California, San Francisco
  • Wei Gu; University of California, San Francisco
  • Steven Miller; University of California, San Francisco
  • Chao-Yang Pan; California Department of Public Health
  • Hugo Guevara; California Department of Public Health
  • Debra Wadford; California Department of Public Health
  • Janice Chen; Mammoth Biosciences, Inc.
  • Charles Y Chiu; University of California, San Francisco
Preprint in English | medRxiv | ID: ppmedrxiv-20032334
ABSTRACT
An outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid ([~]30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2020 Document type: Preprint
...